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Abstract:    
 
The jack jumper ant, Myrmecia pilosula, is endemic to South-Eastern Australia, 
where around 2.7% of the population has a history of systemic allergic reactions 
(anaphylaxis) to its venom. Previous work had indicated that there were several 
allergenic peptides derived from the cDNA Myr p 1, the major expressed allergenic 
product being a 56-residue peptide (Myr p 1 57→112, "pilosulin 1", ~6052 Da).  
Another major allergen had been described as a 27 residue peptide derived from the 
cDNA Myr p 2 (Myr p 2 49→75, "pilosulin 2",  ~3212 Da), possibly existing as part 
of a disulfide complex. As a preliminary step in detailed stability studies of a 
pharmaceutical product used for venom immunotherapy,   LC-MS and Edman 
sequencing analysis of venom collected from various locations by both electrical 
stimulation and venom sac dissection was undertaken. More than 50 peptides in the 
4kDa to 9kDa range were detected in LC-MS analyses. A subsequence of Myr p 2 
was found as part of the major peptide present in all samples; this was a bis-
disulphide linked, antiparallel aligned heterodimer consisting of Myr p 2 49→74, 
(des-Gly27-pilosulin 2, ~3155 Da) and a previously unreported peptide of ~2457 Da. 
Pilosulin 1 was found by a combination of tandem mass spectrometry and Edman 
sequencing to exist mainly, and sometimes exclusively, as a previously unreported 
~6067 Da variant, in which the valine at residue 5 is replaced by isoleucine. A range 
of hydrolysis products of [Ile5]pilosulin 1 and pilosulin 1 were also detected in 
partially degraded venom. Further IgE-binding studies using these peptides are 
warranted and a revision of the nomenclature of allergenic components of M. pilosula 
venom may be required   to conform with established IUIS guidelines. 
 
Keywords: 
 
Jumper ant venom, Myrmecia pilosula,  pilosulins,  Myr p 1,  Myr p 2, heterodimer, 
LC-MS 
3 
Introduction: 
 The “Jack Jumper” ant (Myrmecia pilosula species complex), is a commonly 
encountered member of the genus Myrmecia (“bulldog” and “jumper” ants, 
Hymenoptera: Formicidae: Myrmeciinae) found in southeastern Australia including 
Tasmania and the southernmost tip of Western Australia (Ogata and Taylor, 1991). In 
Tasmania, 2.7% of the population has a history of systemic allergic reactions to jack 
jumper venom (Brown et al., 2003a) and around half of allergic people experience 
life-threatening reactions (Brown et al., 2003a; Clarke 1986; Douglas at al., 1998). 
Deaths have been reported (Brown et al., 2001), and the venom appears to be 
particularly allergenic in comparison to other venoms; in people with a history of 
wasp and bee sting allergy, only 25-50% react to subsequent deliberate sting 
challenges (van Haltern et al., 1996), whereas re-sting reaction rates in people with 
jack jumper sting allergy are 70% for field stings (Brown et al., 2003a) and 72% for 
deliberate sting challenges (Brown et al., 2003b). M. pilosula venom has been shown 
to contain histamine-like, haemolytic, and eicosanoid releasing factors, and to have a 
broad range of enzymatic activity including phospholipase A2, phospholipase B, 
hyaluronidase, acid phosphatase and alkaline phosphatase (Matuszek  et al., 1992; 
Matuszek  et al., 1994). 
 
Previously thought to be a single species, M. pilosula is in fact a karyologically 
diverse species complex, consisting of several sibling species (Crozier et al., 1995; 
Crosland et al., 1988) that may even coexist at a single site (Taylor, 1988). It has 
nevertheless been claimed that IgE binding profiles of electrophoretically separated 
venoms from different regions of Australia, and thus “presumably” from different 
sibling species, are identical (Ford et al., 1991).   
 
Two major protein allergens sharing a common leader sequence have been identified 
via cDNA sequencing (Donovan et al., 1993; Donovan et al., 1994; Donovan et al., 
1995; Street et al., 1996), and found to encode 112 and 75 amino acid residues. The 
cDNA has been named Myr p 1 and Myr p 2 respectively (Figures 1a and 1b). These  
encode precursor peptides that differ by only three amino acids in the first 47 
residues. However, both appear to undergo extensive post-translational modification. 
Donovan et al. (1996) have proposed  (using SDS-PAGE, immunoblotting and 8 
cycles of N-terminal amino acid sequencing) that whole venom contains six 
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subsequences of Myr p 1 (figure 1c), the major IgE binding band being Myr p 1 
57→112. Two other predicted peptide cleavage products of Myr p 1 27→112 and Myr 
p 1 37→112 were not identified in whole venom.  
 
IgE binding bands at 8.5kDa and a broad band at 2-4kDa have been identified as 
being due to the presence of Myr p 2 derived peptides (Donovan et al., 1995). 
Reduction and alkylation of whole venom revealed a single band, which was 
presumed (on the basis of 8 cycles of N-terminal amino acid sequencing) to contain 
Myr p 2 49→75 (Street et al., 1996).  The dual recognition of Myr p 2 is thought to be 
due to the presence of multimeric forms of Myr p 2 49→75 within whole venom 
(Street et al., 1996) and given that Myr p 2 49→75 contains 2 cysteine residues, the 
8.5kDa peptide was proposed to contain Myr p 2 49→75 in a disulfide linked complex 
- either with itself or with another non-allergenic peptide(s) (Donovan et al., 1996).  
Myr p 2 27→75 was previously proposed as a product but was subsequently not 
identified in whole venom via SDS-PAGE (Donovan et al,. 1996). Myr p 1 57→112 
and Myr p 2 49→75 are proposed allergenic products (Donovan et al., 1996) which 
have been named “pilosulin 1” (Wu et al., 1998; Donovan and Baldo, 1999) and 
“pilosulin 2” respectively (Donovan and Baldo, 1997).  From here on the pilosulin 
nomenclature will be used when referring to these peptides. 
 
Pilosulin 1 and pilosulin 2 are extremely basic peptides, with 20% and 33% of their 
residues respectively being lysines or arginines – their theoretical isoelectric points 
are 9.94 and 10.45 respectively (http://ca.expasy.org/tools/pi_tool.html). Pilosulin 1 
has been reported to have significant cytotoxic effects (King et al., 1998; Wu et al., 
1998), and pilosulin 2 has been reported to have antihypertensive properties (Donovan 
and Baldo, 1997). 
 
We recently published a double-blind placebo-controlled trial of jack jumper ant 
venom immunotherapy showing this treatment to be highly efficacious in preventing 
sting anaphylaxis (Brown et al., 2003b). With the aim of establishing a quality control 
regime for our venom extracts, we undertook HPLC-MS analysis of the venom, 
detailed tandem mass spectrometry (MS/MS) sequencing on key peptides and limited 
Edman sequencing  to confirm previous reports of venom composition, and to directly 
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observe the presence of disulfide-bridged dimers suggested by previous investigators 
(Street et al., 1996). 
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Materials and Methods: 
 
Venom collection and storage 
M. pilosula were harvested from a variety of locations around Tasmania for venom 
extraction by either electrostimulation or venom sac dissection.  Electrostimulation 
was performed in the field; live ants were harvested and transferred to a customised 
perspex box. An alternating current was applied across a steel wire grid, inducing 
them to sting a glass plate below, on which the venom rapidly dried. The plates were 
stored on dry ice until return to the laboratory where venom was washed from the 
plates, centrifuged to remove particulate matter, sterilised by filtration through a 0.22 
micron low protein binding filter, lyophilised and weighed to ascertain total 
peptide/protein content. Venom was redissolved in water for injection to produce a 
10mg/ml solution. Aliquots of an amount necessary to formulate pharmaceutical 
batches were prepared and the solutions stored at –80˚C until required. 
 
Ants destined for venom sac dissection were transferred live to the laboratory where 
they were snap frozen and stored at –80˚C. Later the ants were defrosted and under 
aseptic conditions their venom sacs were removed using a dissecting microscope and 
placed in sterile pyrogen-free polypropylene tubes containing water for injection BP. 
Collections of dissected sacs were kept at 0-4 ˚C for no more than 1 hour before being 
refrozen to –80˚C. When at least 3000 sacs had been dissected, the collections were 
defrosted; sacs ruptured using a tissue homogeniser and then processed in the same 
way as electrostimulation venom. Venom collected by electrostimulation was not 
mixed with venom collected via sac dissection at any time.  
 
Fresh samples prepared by both electrostimulation and sac dissection were used for 
HPLC-MS analyses, as were lyophilised samples prepared for therapeutic use. For the 
latter, 10mg/ml venom aliquots were removed from the –80˚C freezer, mixed with 
mannitol and dispensed into 50 or 120 µg aliquots (each containing 20mg mannitol). 
These aliquots were then lyophilised, vacuum-sealed and stored at –8˚C.  
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HPLC-MS    
HPLC analyses were carried out on a Waters Alliance 2690 HPLC, using an Agilent  
Zorbax 300SB-C3 5µm column (2.1mm x 150mm). The solvent system was; Solvent 
A: acetonitrile, Solvent B: 1% trifluoracetic acid, Solvent C: water. The flow rate was 
0.3ml/min. A linear gradient from 10% A, 8% B, 82% C to 70% A, 8% B, 22% C at 
30 min was used in most cases. A slower gradient from 15% A, 8% B, 77% C to 50% 
A, 8% B 43% C at 35 min was used to facilitate specific separations. This was 
followed by a linear gradient to 92% A, 8% B at 45 minutes to flush the column. 
  
The effluent from the HPLC was directly coupled to a Finnigan LCQ equipped with a 
standard electrospray source. The needle Voltage was 5KV, the capillary temperature 
was 250ºC, sheath gas was 70psi and auxiliary gas was 20psi. The range from m/z 100 
to 2000 was typically monitored.  
 
The LC effluent was routinely ‘supercharged’ by post-column addition of 5 ul per 
minute of a 20% glycerol solution (Iavarone et al., 2001). This dramatically increased 
the abundance of higher charge states, making it less likely that larger peptides might 
fall outside the m/z range of the LCQ, and also significantly increased overall 
sensitivity.  Charge states of all key ions were confirmed by higher resolution “zoom 
scans”, using peptides collected by HPLC and subsequent direct infusion still in the 
collection solvent into the electrospray source at 5 ul per minute. 
 
HPLC-UV and Peptide Purification  
HPLC-UV profiles of venom samples were obtained using a Waters 996 diode array 
UV-Vis detector, monitoring wavelengths from 210 to 290 nm. Chromatograms at 
220nm and 280nm were generated from this data. Venom peptides were collected 
from the HPLC effluent (while monitoring the absorbance at 220nm) for subsequent 
reduction, Edman sequencing, trypsin digestion and Q-TOF MS analyses. These 
fractions were stored at –50ºC immediately after collection, and evaporated to dryness 
at 30ºC under a stream of pure dry nitrogen before use. 
 
Reduction and alkylation protocol 
Reduction and alkylation protocols were carried as per Street et al, 1996. Whole 
venom and collected HPLC fractions were reduced by incubation for 30 min at 37ºC 
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in a solution of   ~100µl of reduction reagent (10mM Tris-HCL pH 8.0, 1mM di-Na 
EDTA, 10mM dithiothreitol, 8M urea). Reduced venom fractions were then 
carboxyamidomethylated with iodoacetamide to protect the cysteine thiol groups and 
to readily identify the number of cysteines per peptide chain by mass difference.  This 
was done by mixing an aliquot of the reduced venom fraction with 0.25 volumes of 
0.25M iodoacetamide in 0.25M Tris-HCl at pH 8.0. 
 
Edman Sequencing 
Full and partial Edman sequencing of isolated peptides was undertaken at the 
Australian Proteome Analysis Facility. 
 
Trypsin Digestion 
Venom fractions from HPLC were evaporated to dryness and reconstituted in 25mM 
ammonium bicarbonate. Trypsin (sequencing grade, Sigma Chemicals) was added at 
approximately one fiftieth of the amount of the venom peptide, and the samples were 
incubated at 37OC for 4 hours with occasional shaking, and either immediately 
analysed by HPLC-MS or stored at –50˚C until analysis. 
 
Tandem Mass Spectrometry 
Structural information on the peptides was obtained by ion trap tandem mass 
spectrometry, using a default collision energy of 45%. Molecular clusters of various 
charge states for the main peptides were targeted to gain maximum structural 
information. Microsoft Excel spreadsheets of m/z values of the various charge states 
of predicted key peptide ions based on published structures were generated to 
facilitate interpretation of the data. Additional data was obtained by Q-TOF MS 
analyses undertaken on a Micromass instrument at the Australian Proteome Analysis 
Facility.  
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Results: 
Venom samples from several different batches (either different batches of venom to 
be used therapeutically or samples that were taken immediately following venom 
collection) were analysed, and all gave broadly similar peptide profiles. More than 
fifty peptides were readily detected, all in the 4kDa to 9kDa range. The venom 
samples were dominated by just a few peptides, and a typical chromatogram is shown 
in Figure 2.  Good correlation between LC-UV data and LC-MS data indicated that 
the majority of the peptides were apparently detected in the LC-MS runs. 
 
From deconvolution of electrospray spectra both with and without ‘supercharging’, 
the main peptide in both fresh and stored samples (Peak B in Fig. 2) was found to 
have a molecular weight of ~5608 Da (unless otherwise specified, molecular weights 
listed refer to the averaged rather than monoisotopic weights); from here on for 
convenience this peptide is referred to as ‘pilosulin 3’. Direct MS/MS data of 
pilosulin 3 was beyond direct sequencing due to its expected complexity, and no 
immediate correlation with the published major peptides was apparent. However, on 
the theory that this major peptide might contain the previously reported pilosulin 2 as 
a disulfide complex, the y ions (Roepstorff and Fohlman, 1984) were calculated for 
the neutral losses from the N-terminal end of pilosulin 2 from such a complex. These 
ions were observed for the first 10 residues from the N-terminus of pilosulin 2  (Fig 
3), initially supporting the presence of this known peptide. Reduction of pilosulin 3 
resulted in peptides of  ~3155 and ~2457 Da, confirming it as a heterodimeric peptide. 
However, the predicted peptides were ~3212 Da (pilosulin 2) and either ~2400 or 
~2398 Da (depending on the number of disulfide bonds) if pilosulin 3  consisted of 
pilosulin 2 disulfide bonded to a smaller peptide. The 4 Da difference between the 
sum of the molecular weights of the reduced peptides and the molecular weight of the 
original dimer nevertheless indicated the presence of two disulfide bonds.   
 
Carboxyamidomethylation of the reduced peptides also supported this interpretation, 
with two cysteines indicated on each peptide by the shift of 114 Da from ~3155 to 
~3269 and from ~2457 to  ~2571 Da.  Detailed MS/MS investigation of the ~3155 Da 
peptide, which by mass was approximately one glycine residue short of pilosulin 2, 
indicated that it was indeed consistent by direct MS sequence data to pilosulin 2 
minus the C-terminal glycine (‘des-Gly27-pilosulin 2’, Myr p 2 49→74, see Fig. 4). 
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MS/MS data from several charge states of carboxyamidomethylated des-Gly27-
pilosulin 2 at ~3269 Da also strongly supported this assignment.   
 
The 2457 Da peptide (hereafter referred to as ‘pilosulin 3b’)  was subsequently 
isolated by HPLC as its carboxyamidomethylated derivative and fully sequenced by 
N-terminal Edman degradation. This resulted in the unequivocal 23 amino acid 
sequence,  
 
L I G L V S K G T C V L V K T V C K K V L K Q  
 
which was unrelated to either Myr p 1 or Myr p 2. Evidence from both Q-TOF and 
ion trap tandem MS of this peptide strongly supported this sequence, and also 
indicated that the C-terminus was amidated, resulting in a calculated mass of  2457.3 
Da. Fig 5 shows the ion trap MS/MS data from the 2+ ion of   
carboxyamidomethylated pilosulin 3b, with assignments consistent with the Edman 
data. The expected mass shifts were also observed for appropriate product ions 
between  raw pilosulin 3b and its carboxyamidomethylated derivative. 
 
The unique disulfide bridged peptides that would result from trypsin digestion were 
calculated for pilosulin 3 for both parallel and antiparallel chain alignment; predicted 
peptides for the former were 767.4 and 1066.5 Da (monoisotopic weights) and for the 
latter 797.4 and 1036.5 Da (monoisotopic weights). A trypsin digest of  pilosulin 3 
resulted in a very prominent peptide with an [M+2H]2+ ion at m/z 519.2 with an 
isotope pattern that strongly supported the presence of  two cysteine residues. This 
was consistent with the 1036.5 Da disulfide bridged dimer; 
 
  
and indicated that pilosulin 3 consisted  of an antiparallel alignment of the des-Gly27-
pilosulin 2 and pilosulin 3b chains.  MS/MS data from m/z 519.2 was consistent with 
the expected peptide, with many ions directly assignable to this trypsin fragment 
diagnostic for antiparallel alignment (Fig 6).  
 
Trypsin cleavage products of native pilosulin 3 also supported the des-Gly27-pilosulin 
2 sequence, with strong singly charged ions (monoisotopic values)  at m/z 561 
 
A C K              G T C V L V K 
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(residues 1→4),  490 (residues 18→21) and m/z 278 (putative residues 25→26).  The 
latter was supported by residue specific MS/MS product ions at m/z 120 (from 
phenylalanine) and m/z 86 (leucine immonium ion); however, this  implied C-terminal 
amidation of the des-Gly27-pilosulin 2 sequence since a Phe-Leu dipeptide would 
produce an [M+H]+ ion at m/z 279. There were also weak  y3, y4, y5 and y6 ions at m/z 
406, 509, 580 and 708 (monoisotopic values) from the non-alkylated des-Gly27-
pilosulin 2 obtained by reduction, and y4 and  y5 ions for its alkylated version at m/z 
566 and 637 (monoisotopic values). The predicted monoisotopic m/z values for these 
without C-terminal amidation of the leucine at position 26 are 407, 510, 581 and 709 
for the non-alkylated  form and 567 and 638 for the two observed ions from  the 
alkylated form. The calculated mass of des-Gly27-pilosulin 2 with C-terminal 
amidation is 3153.9 Da, and the calculated mass of pilosulin 3 is then 5607.2 Da.  
 
Peak C in Figure 2 gave MS data indistinguishable from pilosulin 3 by ion trap MS, 
with the same molecular weight and all directly observable sequence data was 
identical. Reduction of whole venom resulted in two peaks at ~2457 Da in the same 
proportions as peaks B and C, but only one peak at ~3155 Da, indicating that peak C 
contains an isomass variant of pilosulin 3b. 
 
Another variant of pilosulin 3 had a molecular weight of ~5667 Da. This coeluted 
with pilosulin 3 and from reduction was found to be comprised of des-Gly27-pilosulin 
2 and a  ~ 2514 Da variant of pilosulin 3b which also coeluted with it. Tandem MS 
data indicated this to have an additional C-terminal glycine. This variant was typically 
about 20% of the abundance of pilosulin 3. 
 
 
 
 
 
 
 
 
 
L I G L V S K G T C V L V K T V C K K V L K Q-NH2
I D W K K V D W K K V S K K T C K V M L K A C K F L-NH2
Pilosulin 3  (Peak B, Fig. 2)
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A peak consistent in mass with pilosulin 1 was directly detected in most venom 
samples as a relatively minor component.  Peak D in Figure 2 indicated a peptide of 
~6052 Da, and while well beyond full direct sequencing by MS, sequence data 
observed from several charge states was consistent with the published sequence of 
pilosulin 1.   
 
There was also strong supporting evidence for Myr p 1 65→112 as a minor 
component in all venom samples analysed, and Myr p 1 subsequences starting from 
position 63 right through to starting from position 72  (all terminating at position 112) 
were detected in partially degraded venom samples. Several of these corresponded to 
previously reported peptides (Donovan et al., 1996). 
 
However, pilosulin 1 was observed in all samples mainly as a ~6067 Da   variant 
(Peak E in Figure 2) .  MS/MS sequence data indicated a very high degree of 
homology with pilosulin 1, for which all ‘b’ type ions from b23 to b54 were observed. 
Given the relative lack of mass accuracy at these values on the ion trap instrument 
used, initially oxidation of a methionine (+16 Da) or post-translational methylation of 
a lysine (+14 Da) were considered as possibilities for this peptide, although the 
significantly later retention time made the former explanation less likely. Direct 
MS/MS data was only sufficient to indicate that any differences occurred between 
residues 1 and 22, as all b ions from b23 to b54 were shifted by ~14 Da relative to 
pilosulin 1. The presence of three arginine residues in this region may have inhibited 
the formation of suitable diagnostic ions (Tang et al., 1993; Dongre, 1996).   
Subsequences starting from position 7 of pilosulin 1, as described above, were also 
observed in a slightly degraded stored sample that had initially had no pilosulin 1.   If 
these were derived from the 6067 Da peptide, this indicated  the difference of the 
variant from pilosulin 1 was in the first 6 residues. This made post-translational 
modification a less likely explanation due to the reported residues in these positions 
(Gly-Leu-Gly-Ser-Val-Phe), so this peptide was investigated further as a genuine 
variant of pilosulin 1. Trypsin digestion resulted in a prominent peptide at 805.4 Da 
(monoisotopic weight) rather than at 791.4 (monoisotopic weight) as required for the 
pilosulin 1 trypsin digest fragment [residues 1-8], also confirming the difference was 
in the first 8 residues. First principles MS/MS interpretation on this indicated a 
leucine or isoleucine at position 5 in place of the valine in pilosulin 1, since all a, b 
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and c type ions (Roepstorff and Fohlman, 1984) numbered from 5 onwards were 14 
Da higher than for the analogous pilosulin 1 trypsin digest peptide. Similarly y and z 
ions numbered from 4 onwards were 14 Da higher.   
 
Partial Edman sequencing (10 cycles) of the purified 6067 Da pilosulin 1 variant   
confirmed isoleucine in place of valine at position 5 (‘[Ile5]pilosulin 1’), consistent 
with the ~14 Da difference in molecular weights and with the MS/MS data.  Neither 
variant of pilosulin 1 showed any significant absorbance at 280nm by LC-UV 
analysis, consistent with an absence of aromatic amino acid residues.  
 
A minor homologous peptide at ~6082 Da eluting just before [Ile5]pilosulin 1 was 
assigned as an oxidized form of [Ile5]pilosulin 1, due to its increased abundance in 
some stored samples. 
 
Peak A in Figure 2 had a molecular weight of ~ 5545 Da and  was unaltered by 
reduction, indicating it to be a monomer. It showed some absorbance at 280nm, 
indicating it contained more aromatic amino acid residues than pilosulin 1. No peptide 
of this weight could be derived from subsequences of Myr p 2 and MS/MS data did 
not  show any relationship between it and any of the hypothetical subsequences of 
Myr p 1 or its [Ile5] pilosulin 1 variant that were near this weight. This remains to be 
confirmed as amino acid sequences of this and all other minor peptides remain to be 
determined. 
 
To investigate the possibility of genetic variation contributing to our findings using 
Tasmanian venoms, a lyophilised internal reference sample produced by the 
Commonwealth Serum Laboratories from Victorian specimens by venom sac 
dissection in the early 1990s (provided courtesy of Dr Brian Baldo) was also 
analysed. This was found to contain the same range of major peptides, with the [Ile5] 
variant also more abundant than pilosulin 1. 
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Discussion: 
This work has confirmed previous theories that the major peptide in jack jumper 
venom is a disulfide complex. We have found this complex be to comprised of a 
previously unreported subsequence from Myr p 2 and a novel smaller peptide with C-
terminal amidation. N-terminal sequencing has previously been used to identify Myr p 
1 and Myr p 2 derived polypeptides (Donovan et al., 1996). The 8 cycles used would 
have been insufficient to detect the lack of a glycine residue, as predicted from the 
known cDNA sequence, at the C-terminal of des-Gly27-pilosulin 2.  
 
Although most allergic sera appear to bind to peptides derived from Myr p 1 and Myr 
p 2, Radioallergosorbent Test (RAST) studies using these synthetic peptides have 
indicated that a proportion of sera that recognise native venom do not recognise 
synthetically prepared peptides (Dr. Brian Baldo, personal communication). These 
findings might be explained by inaccuracies in our current understanding of peptide 
structure in the native venom. We initially postulated that IgE reacting to synthetic 
Myr p 2 subsequences recognised parts “visible” to IgE from within pilosulin 3, as 
Myr p 2 49→74 is the only form to date that we have recognized any Myr p 2 
subsequence in the native venom (existing in pilosulin 3  and its  variants ). However, 
since completing our study, we have been made aware that the heterodimer that we 
describe here as pilosulin 3 had been previously identified in unpublished work (Dr 
Brian Baldo and Professor Paul Alewood, personal communication) which also found 
relatively low IgE recognition of a synthetic version of the heterodimer, despite 
recognition of Myr p 2 (Dr Brian Baldo, personal communication;  Dr Qi Xuan Wu,  
2001,  including original RAST data from 67 of our Tasmanian patients). This 
presents an interesting problem, given that we have so far been unable to identify Myr 
p 2 in any form other than these closely related heterodimers.  Amino acid sequence 
data from the majority of minor peptides present in venom is still lacking, and the 
possibility that other subsequences of Myr p 2 are present in venom as minor 
abundance peptides cannot be excluded. Therefore we believe that further IgE-
binding studies are required, and one method would be to use gel-separated native 
venom components for which MS has confirmed the identity of the peptides 
comprising each  band.  
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We also found that pilosulin 1 is a relatively minor constituent of the venom as its 
published sequence and that a minor variant of it exists in much greater abundance. 
This  is not surprising, as the presence of numerous isoforms of venom peptides has 
been reported before in ants. The tropical ant Pseudomyrmex triplarinus has a 
complex venom that includes at least 6 myrmexin isoforms, ranging from 6998 to 
7142 Da. (Pan and Hink, 2000). These all appeared within one band on SDS-PAGE 
(Hink et al., 1994).  Ponericins from Pachycondyla goeldii venom (Orivel et al., 2001)  
have also been shown to exist as one or more closely related isoforms.   Pilosulin 1 
and its [Ile5] variant would migrate as a single band on SDS-PAGE due to their 
similar molecular weights. In addition, their calculated isoelectric points are identical  
(pI=10.45). A similar scenario, where the molecular weights are similar and the 
isoelectric points identical (pI=9.94),   exists for pilosulin 2 and des-Gly27-pilosulin 2. 
Neither isoelectric focusing and/or 2D SDS-PAGE would  be likely to be useful in 
these separations, and this underlines the importance of HPLC in the separation of 
such closely related peptides.  
 
The possibility of genetic variation explaining the apparent difference from published 
data was considered. We analysed venom samples from several different sources 
within Tasmania and an earlier reference sample from Victoria that was used by 
previous investigators. All gave very similar peptide profiles, with the exception that 
in some samples, pilosulin 1 was only detected as the [Ile5] variant. There was no 
obvious difference between venom samples obtained by electrostimulation and those 
obtained by venom sac dissection. Donovan et al (1994) have determined that 
residues 93 →106 of Myr p 1 contain the IgE binding determinant(s). Given this, and 
the subtle differences between [Ile5]pilosulin 1 and pilosulin 1 with respect to primary 
amino acid structure, it is unlikely that the IgE binding capacity of these two variants 
of pilosulin 1 will differ greatly. Nevertheless this must be confirmed by further 
research. 
 
Direct examination of M. pilosula venom peptides by HPLC-MS has resulted in the 
identification of the major expressed forms of allergenic peptides. Detailed tandem 
mass spectrometry analysis has confirmed the presence of Myr p 1 and Myr p 2 
subsequences within the venom, and has also enabled the identification of post-
translational modifications of the allergenic peptides. Detailed stability studies of M. 
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pilosula venom extract produced for human immunotherapy can now be performed 
with a clearer understanding of the peptides involved. However, further research into 
the binding affinity of venom-specific IgE for the various native venom components, 
including pilosulin 3 and its variants, is required. This will enable firm “pass fail” 
criteria to be drawn up for diagnostic and therapeutic venom extracts. The possibility 
of co-existing subspecies of M. pilosula being responsible for the various isoforms 
also requires further exploration. If significant differences in IgE binding are 
identified, this knowledge will ensure that a consistent mix of venom allergens is 
produced from representative sub-species. It is now apparent that to conform to 
established IUIS guidelines (King et al., 1995) a revision of the nomenclature of 
allergenic components of M. pilosula venom may be required. 
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Figure Captions: 
 
Figure 1   
Published Myr p 1 and Myr p 2   (cDNA-derived) sequences, and previously proposed 
subsequences in expressed jack jumper venom. Pilosulin 1 and pilosulin 2 sequences 
are in bold. 
 
Figure 2  
Typical Myrmecia pilosula venom HPLC-MS Total Ion Chromatogram  
 
A = ~5545 Da monomeric peptide (unidentified) 
B = ‘pilosulin 3’,  ~5608 Da bis-disulfide bonded, antiparallel aligned heterodimer, 
consisting of des-Gly27-pilosulin 2 plus  a novel 2457 Da peptide (‘pilosulin 3b’) , 
each with C-terminal amidation. 
C = variant of pilosulin 3  
D = pilosulin 1 (~6052 Da) 
E = [Ile5]pilosulin 1  (~6067 Da) 
 
  
 
Figure 3 
Expanded regions of ion trap MS/MS product ions of the [M+4H]4+ ion at m/z 1403 
from the ~5608 Da dimer.    Y and B represent ions from the putative pilosulin 2 
chain, y23 represents the intact smaller peptide. Final assignments of amino acid 
number for the Ymyn ions were based on data from reduced venom (see Results). 
 
Figure 4  
Ion trap product ion spectrum from the [M+3H]3+ ion  at m/z 1053 of   the larger 
peptide (~3155 Da) obtained after reduction of  peak B (‘pilosulin 3’). This was ~57 
Da lower than expected for pilosulin 2; interpretation of the tandem MS data from 
first principles  and trypsin digest peptides indicated that it was consistent with des-
Gly27-pilosulin 2 with C-terminal amidation, for which some assignments are shown. 
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Figure 5 
Ion trap MS/MS product ions from the   [M+2H]2+ ion at  m/z 1286  of   the 
carboxymethylated  ~2457  Da   novel peptide (‘pilosulin 3b’)  obtained from reduction of 
pilosulin 3. Edman sequencing and Q-TOF MS/MS indicated this to be; 
 L I G L V S K G T C V L V K T V C K K V L K Q-NH2.  
Individual ion assignments are derived from this. 
 
Figure 6 
Ion trap product ions and their assignments from the diagnostic trypsin cleavage 
product: 
 
 
from pilosulin 3 giving unequivocal data on the alignment of the two chains . Capital 
letters represent peptide sequences originating from  ACK  derived from des-Gly27-
pilosulin 2, lower case represents sequences originating from GTCVLVK  derived 
from pilosulin 3b. 
 
 
  
 
 
 
A C K              G T C V L V K 
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Figure 1 
 
A 
Myr p 1 
    5     10     15     20 
Met  Lys Leu Ser Cys Leu Leu Leu Thr Leu Ala Ile Ile Phe Val Leu Thr Ile Val His 
        25         30         35        40 
Ala Pro Asn Val Glu Ala Lys Asp Leu Ala Asp Pro Glu Ser Glu Ala Val Gly Phe Ala 
    45     50     55     60 
Asp Ala Phe Gly Glu Ala Asp Ala Val Gly Glu Ala Asp Pro Asn Ala Gly Leu Gly Ser 
    65     70         75           
Val Phe Gly Arg Leu Ala Arg Ile Leu Gly Arg Val Ile Pro Lys Val Ala Lys Lys Leu 
        85         90         95         100 
Gly Pro Lys Val Ala Lys Val Leu Pro Lys Val Met Lys Glu Ala Ile Pro Met Ala Val 
        105         110             
Glu Met Ala Lys Ser Gln Glu Glu Gln Gln Pro Gln         
 
B 
Myr p 2 
    5     10     15     20 
Met  Lys Leu Ser Cys Leu Leu Leu Thr Leu Ala Ile Ile Phe Val Leu Thr Ile Val His 
        25         30         35        40 
Ala Pro Asn Val Glu Ala Lys Ala Leu Ala Asp Pro Glu Ser Asp Ala Val Gly Phe Ala 
    45     50     55     60 
Asp Ala Val Gly Glu Ala Asp Pro Ile Asp Trp Lys Lys Val Asp Trp Lys Lys Val Ser 
    65     70         75           
Lys Lys Thr Cys Lys Val Met Leu Lys Ala Cys Lys Phe Leu Gly 
 
C 
     Isotopic Average Mol Wt 
Myr p 1 57 → 112 (pilosulin 1)     6052   
Myr p 2 49 → 75 (pilosulin 2)        3212   
Myr p 1 68 → 112    4938      
Myr p 1 65 → 112    5279    
Myr p 1 71 → 112    4655     
Myr p 1 86 → 112    3069 
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Figure 3 
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Table 1 
 
Molecular weights of   peptides easily  observed in  Myrmecia 
pilosula   venom by  LC-MS.  Based on observations from dozens of 
venom samples, the  more abundant peptides are in bold, with these 
typically accounting for at least 80% of the peptide total ion 
chromatogram. 
   
 
 
Molecular Weight  
(daltons) 
 
Retention 
Time 
 
 
Identity 
   
~4938 18.5 Myr p 1 68→112 
~5089 13.1  
~5104 12.5  
~5166 18.5  
~5279 19.0 Myr p 1 65→112 
~5467 22.0  
~5545 (Peak A, Fig 2) 13.1 Unidentified  monomer 
 
~5608 ( Peak B, Fig 2) 
22.5 ‘pilosulin 3’ - antiparallel aligned heterodimer of des-Gly27-
pilosulin 2 (Myr p 2 49 → 74)  and a novel 2457 Da peptide 
(‘pilosulin 3b’). Both peptides are C-terminally amidated 
~5608 (Peak C, Fig 2) 24.2 variant of pilosulin 3 
~5667 22.5 dimer of of des-Gly27-pilosulin 2 and a novel  ~2514 Da 
peptide; coelutes with peak B 
~5725 22.2  
~5835 16.6  
~5925 15.5  
~6016 17.4  
~6032 14.7  
~6052 (Peak D, Fig.2) 25.7 pilosulin 1  (Myr p 1 57 → 112) 
~6067 (Peak E, Fig. 2) 27.4 [Ile5]pilosulin 1 
~6082 26.7 oxidized [Ile5]pilosulin 1 
~6305 21.5  
~6639 12.5  
~8198 23.4  
~8546 28.4  
 
